Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with ...
Hosted on MSN1mon
Glucotrack soars on completion of first human clinical study of continuous blood glucose monitorGlucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time ...
(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology company focused on innovative diabetes solutions, on Tuesday announced the successful completion of its first in-human clinical study for ...
people with diabetes announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose ...
Hosted on MSN1mon
Glucotrack announces 1-for-20 reverse stock splitRUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ:GCTK), a medical device company specializing in diabetes care technology, has announced a 1-for-20 reverse stock split of its issued and outstanding ...
(RTTNews) - Glucotrack, Inc. (GCTK), Wednesday, announced the results from its first-in-human trial of its continuous blood glucose monitoring or CBGM system, which will be presented at the 2025 ...
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The company’s ...
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback